Biofrontera Inc. (BFRI) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US09077D2099
Biofrontera Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 41.71 m USD |
| Operating income | -11.35 m USD |
| EBIT | -10.51 m USD |
| Net income | -10.54 m USD |
| Diluted EPS – continuing operations | -1.04 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
More stocks
- Stimcell Energetics Inc. (STME)
- Tempest Therapeutics, Inc. (TPST)
- Sky Quarry Inc. (SKYQ)
- Oncotelic Therapeutics, Inc. (OTLC)
- Blue Star Foods Corp. (BSFC)
- Mag Mile Capital, Inc. (MMCP)
- Sonendo, Inc. (SONX)
- BAB, INC. (BABB)
- Worksport Ltd (WKSP)
- INNOVATIVE FOOD HOLDINGS INC (IVFH)
- Verde Clean Fuels, Inc. (VGAS)
- Aspira Women's Health Inc. (AWHL)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.